Prostate Cancer Pipeline & Marketplace Investigated by GBI Research in Topical Report Now Available at MarketPublishers.com06 Jan 2015 • by Natalie Aster
LONDON – Over the past decade, the oncology and the prostate cancer marketplace in particular have seen the clinical and commercial influence of targeted therapies geared to targeting proteins in signaling pathways associated with the progression of the disease.
The prostate cancer drug pipeline boasts around 484 products in active development across all stages. The scope of mechanisms of action (MoA) that these compounds employ is also highly versatile, particularly in contrast with the current market landscape. The proportion and degree of breakthrough innovations in the pipeline reviewed is exceptional; there have been 174 first-in-class programmes detected in the prostate cancer pipeline, which are acting on 122 best-in-class molecular targets. This comprises close to 36% of all products with a molecular target disclosed and reflects the high level of innovation in the disease. This has far-reaching strategic implications for all market participants, as many of the first-in-class technologies are likely to reach the market in the next ten years and transform the commercial and clinical landscape.
Topical research report “Frontier Pharma: Prostate Cancer - Identifying and Commercializing First-in-Class Innovation” elaborated by GBI Research comprises an in-depth analysis of the overall prostate cancer pipeline and the present-day market landscape. It analyses the deals landscape gathering around top-of-the-range products in prostate cancer, and determines a slew of opportunities for in licensing.
The study presents a brief review of the indication, examines the evolving molecular target landscape between pipeline and market along with discussing innovations in the market. It comprehensively reviews the pipeline for first-in-class treatment options, analysed based on the phase of development, molecular target and molecule type; identifies and assesses first-in-class molecular targets with a specific focus on early-stage programmes of which clinical utility has to be assessed, and also literature surveys of new molecular targets. An in-depth assessment of the co-development and licensing deals landscape for prostate cancer treatment modalities and benchmarking of deals encompassing non-first-in-class versus first-in-class products can also be found in the report.
Frontier Pharma: Prostate Cancer - Identifying and Commercializing First-in-Class Innovation
Published: November, 2014
Price: US$ 6,995.00
More topical market studies by the publisher can be found at GBI Research page.